FINWIRES · TerminalLIVE
FINWIRES

Update: Climb Bio Shares Fall After Early Phase 1 Data for IgA Nephropathy Drug

By

(Updates with the company's stock move in the headline and the first paragraph.)

Climb Bio (CLYM) shares were down 3.7% in Thursday trading after its phase 1 trial data for its experimental antibody treatment CLYM116 demonstrated a 29-day half-life that supports dosing every 12 weeks for patients with IgA nephropathy.

A single 320-milligram dose achieved nearly complete protein suppression and lowered specific antibody levels by 60% to 75% over a 12-week period, the company said.

The kidney disease drug candidate was generally well-tolerated without any serious adverse events or dose-limiting toxicities, it said.

The company plans to release initial findings from an ongoing phase 2 trial during H1 of 2027, and to start a phase 3 study in 2027, Climb Bio said.

Price: $14.50, Change: $-0.55, Percent Change: -3.65%

Related Articles

Wire

Ionic Rare Earths Strikes Magnet Recycling Joint Venture Agreement With US Strategic Metals; Shares Rise 10%

Ionic Rare Earths (ASX:IXR) unit Ionic Rare Earths USA struck a joint venture agreement with US Strategic Metals to build magnet recycling facilities at the latter's fully permitted site in Missouri, US, according to a Thursday filing with the Australian bourse.The new term sheet supersedes and "materially advance" the memorandum of understanding the parties struck in November 2025, per the filing.The parties agreed on a non-binding basis to form a 50-50 joint venture to develop an integrated campus for the production of critical minerals and metals at the Missouri site. The proposed joint venture aims to construct one or more magnet and other rare earth recycling facilities, processing recycled permanent neodymium-iron-boron and samarium-cobalt magnets and magnet scrap, and also plans to evaluate the recycling of other heavy rare earth elements.Ionic Rare Earths' Belfast subsidiary, Ionic Technologies, will contribute a non-exclusive license to the joint venture for its magnet recycling technology.The planned venture will be funded with $100 million for the construction of initial recycling facilities, comprised of $95 million in funding from US Strategic Metals and a $5 million equity contribution split equally between Ionic Rare Earths USA and US Strategic Metals.Ionic Rare Earths shares jumped over 10% in recent Thursday trade.

ASX:IXR
Wire

Ultragenyx Says Phase 3 Study on Rare Neurogenetic Disorder Missed Primary, Secondary Endpoints; Shares Fall After-Hours

Ultragenyx Pharmaceutical (RARE) said late Wednesday the phase 3 Aspire study of apazunersen in Angelman syndrome, a rare, neurogenetic disorder, did not achieve its primary endpoint or its key secondary endpoint.The late-stage study did not reach the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index, according to a statement.The safety profile for the phase 3 trial remained consistent with phase 1 and phase 2, the company said.Ultragenyx said it will assess the apazunersen program following this outcome and make a decision on its disposition.Shares of Ultragenyx were down about 45% in after-hours trading.

$RARE
Wire

ChargePoint Q2 Loss Narrows, Revenue Rises

ChargePoint (CHPT) reported Wednesday Q2 loss of $1.35 per diluted share, compared with a loss of $2.85 a year earlier.Analysts polled by FactSet expected loss of $1.57.Revenue for the quarter ended July 31 was $116.1 million, up from $98.6 million a year ago.Analysts expected $105.2 million.ChargePoint expects Q3 revenue of $105 million to $115 million. Analysts expect $109.3 million.Shares of the company rose over 17% in after-hours trading.

$CHPT